Compare GGR & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGR | NRXS |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 46.3M |
| IPO Year | N/A | 2023 |
| Metric | GGR | NRXS |
|---|---|---|
| Price | $3.05 | $5.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 10.9K | ★ 76.1K |
| Earning Date | 02-12-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,211,000.00 | $3,362,320.00 |
| Revenue This Year | N/A | $31.05 |
| Revenue Next Year | $6.15 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.89 |
| 52 Week Low | $2.72 | $1.33 |
| 52 Week High | $10.00 | $6.20 |
| Indicator | GGR | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 52.18 |
| Support Level | $2.82 | $4.50 |
| Resistance Level | $3.14 | $5.14 |
| Average True Range (ATR) | 0.13 | 0.32 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 36.78 | 37.99 |
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).